A Open-label Study to Assess the Safety of Oral Long-term Use of SA-001 in Pancreatic Exocrine Insufficiency

Study Identifier
S245.3.123
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete

Results Available

Scientific Result Summary
Available Language(s): English

Study Details

Medical Condition
  • Liver, Pancreas & Gallbladder - Other
  • Study Drug
  • SA-001
  • Phase
    Phase 3
    Sex
    Female & Male
    Age
    20+ years

    Protocol Summary

    This study is to evaluate the safety of 3.0 g/day of SA-001 (to be flexibly increased or

    decreased with the range from 1.5 g/day to 6.0 g/day), which will orally be administered for

    52 weeks to patients with pancreatic exocrine insufficiency caused by chronic pancreatitis in

    the non-compensatory stage or by pancreatectomy.

    Study Locations

    Location
    Status
    Location
    Site Reference ID/Investigator# 45211
    Fukuoka, Japan
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 45297
    Fukuoka, Japan
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 45220
    Hiroshima, Japan
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 45279
    Hiroshima, Japan
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 45223
    Hokkaido, Japan
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 45303
    Hokkaido, Japan
    Status
    Not applicable
    Showing {first} - {last} of {total} Results